Table 1.
Training set (n=157) | Development set (n=40) | Validation set (n=100) | p-valuea) | |
---|---|---|---|---|
Age (yr) | 50 (28-80) | 49 (30-68) | 47 (34-75) | |
Sex | ||||
Female | 157 (100) | 40 (100) | 100 (100) | > 0.99 |
Metastatic carcinoma | ||||
Present, size > 2 mm | 68 (43.3) | 14 (35.0) | 40 (40.0) | 0.158 |
Present, size ≤ 2 mm | 35 (22.3) | 5 (12.5) | 15 (15.0) | |
Absent | 54 (34.4) | 21 (52.5) | 45 (45.0) | |
Neoadjuvant systemic therapy | ||||
Not received | 80 (51.0) | 28 (70.0) | 45 (45.0) | 0.027 |
Received | 77 (49.0) | 12 (30.0) | 55 (55.0) | |
Histologic type | ||||
IDC | 149 (94.9) | 32 (80.0) | 86 (86.0) | 0.005b) |
ILC | 8 (5.1) | 5 (12.5) | 11 (11.0) | |
MC | 0 | 0 | 3 (3.0) | |
Metaplastic carcinoma | 0 | 3 (7.5) | 0 | |
Histologic grade | ||||
1 or 2 | 118 (75.2) | 34 (85.0) | 86 (86.0) | 0.074 |
3 | 39 (24.8) | 6 (15.0) | 14 (14.0) |
Values are presented as median (range) or number (%). IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MC, mucinous carcinoma.
p-values, calculated using the chi-square test,
For the histologic type, a chi-square test was conducted between IDC and non-IDC.